ZA200305545B - Mycoplasma hyopneumoniae bacterin vaccine. - Google Patents
Mycoplasma hyopneumoniae bacterin vaccine. Download PDFInfo
- Publication number
- ZA200305545B ZA200305545B ZA200305545A ZA200305545A ZA200305545B ZA 200305545 B ZA200305545 B ZA 200305545B ZA 200305545 A ZA200305545 A ZA 200305545A ZA 200305545 A ZA200305545 A ZA 200305545A ZA 200305545 B ZA200305545 B ZA 200305545B
- Authority
- ZA
- South Africa
- Prior art keywords
- vaccine composition
- vaccine
- mixture
- pigs
- acrylic acid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 101
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 title claims description 74
- 239000000203 mixture Substances 0.000 claims description 83
- 229920002125 Sokalan® Polymers 0.000 claims description 33
- 239000002671 adjuvant Substances 0.000 claims description 33
- 241001465754 Metazoa Species 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 23
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 22
- 230000036039 immunity Effects 0.000 claims description 19
- 229920001400 block copolymer Polymers 0.000 claims description 16
- 230000001681 protective effect Effects 0.000 claims description 14
- -1 terpene hydrocarbons Chemical class 0.000 claims description 14
- 241000204031 Mycoplasma Species 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 230000003053 immunization Effects 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 11
- 229930195733 hydrocarbon Natural products 0.000 claims description 9
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 9
- 229940032094 squalane Drugs 0.000 claims description 9
- 235000007586 terpenes Nutrition 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229940031439 squalene Drugs 0.000 claims description 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 4
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 claims description 3
- 241000588779 Bordetella bronchiseptica Species 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 3
- 241000589902 Leptospira Species 0.000 claims description 3
- 241000606860 Pasteurella Species 0.000 claims description 3
- 241001138501 Salmonella enterica Species 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 241000282887 Suidae Species 0.000 description 104
- 210000004072 lung Anatomy 0.000 description 48
- 230000003902 lesion Effects 0.000 description 43
- 238000012360 testing method Methods 0.000 description 36
- 238000002255 vaccination Methods 0.000 description 34
- 210000002966 serum Anatomy 0.000 description 28
- 241000282898 Sus scrofa Species 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 11
- 239000012895 dilution Substances 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229920001983 poloxamer Polymers 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000000405 serological effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000008157 ELISA kit Methods 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 4
- 229940033663 thimerosal Drugs 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 3
- 229920011250 Polypropylene Block Copolymer Polymers 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 235000020030 perry Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000204003 Mycoplasmatales Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 229940052907 telazol Drugs 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000202938 Mycoplasma hyorhinis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035724 Pneumonia mycoplasmal Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- HVYLDJKDVOOTHV-UHFFFAOYSA-N acetic acid;2-iminoethanethiol Chemical compound CC(O)=O.CC(O)=O.SCC=N HVYLDJKDVOOTHV-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004726 long-term protective immunity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 201000006509 pleuropneumonia Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- HQOJMTATBXYHNR-UHFFFAOYSA-M thallium(I) acetate Chemical compound [Tl+].CC([O-])=O HQOJMTATBXYHNR-UHFFFAOYSA-M 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25663700P | 2000-12-19 | 2000-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200305545B true ZA200305545B (en) | 2004-10-18 |
Family
ID=22972978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200305545A ZA200305545B (en) | 2000-12-19 | 2003-07-17 | Mycoplasma hyopneumoniae bacterin vaccine. |
Country Status (28)
Country | Link |
---|---|
US (4) | US20020131980A1 (de) |
EP (1) | EP1343525B1 (de) |
JP (2) | JP5074656B2 (de) |
KR (1) | KR100874119B1 (de) |
CN (1) | CN1296095C (de) |
AR (1) | AR033410A1 (de) |
AT (1) | ATE359813T1 (de) |
AU (2) | AU2002228993B2 (de) |
BG (1) | BG66213B1 (de) |
BR (1) | BRPI0116249B1 (de) |
CY (1) | CY1106669T1 (de) |
CZ (1) | CZ307075B6 (de) |
DE (1) | DE60127994T2 (de) |
DK (1) | DK1343525T3 (de) |
ES (1) | ES2283452T3 (de) |
HK (1) | HK1056513A1 (de) |
HR (1) | HRP20030585B1 (de) |
HU (1) | HU227431B1 (de) |
ME (1) | ME00570B (de) |
MX (1) | MXPA03005357A (de) |
MY (1) | MY129765A (de) |
NZ (1) | NZ526904A (de) |
PL (1) | PL211174B1 (de) |
PT (1) | PT1343525E (de) |
RS (1) | RS51536B (de) |
TW (1) | TWI308872B (de) |
WO (1) | WO2002049666A2 (de) |
ZA (1) | ZA200305545B (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY129765A (en) * | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
US7018638B2 (en) * | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
GB0400264D0 (en) * | 2004-01-07 | 2004-02-11 | Polytherics Ltd | Complexes |
UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
HUE029552T2 (en) | 2005-12-29 | 2017-03-28 | Boehringer Ingelheim Vetmedica Inc | Use of PCV2 immunogenic composition to reduce clinical symptoms in piglets |
ES2814473T3 (es) | 2005-12-29 | 2021-03-29 | Boehringer Ingelheim Animal Health Usa Inc | Composiciones inmunogénicas de PCV2 multivalentes y métodos para producir dichas composiciones |
EP2101815A4 (de) | 2006-12-11 | 2010-10-06 | Boehringer Ingelheim Vetmed | Wirksames verfahren zur behandlung von infektionen mit porcinem circovirus und lawsonia intracellularis |
EP3466442A1 (de) | 2006-12-15 | 2019-04-10 | Boehringer Ingelheim Vetmedica, Inc. | Behandlung von mda seropositiven schweinen mit pcv2-antigen |
EP1941903A1 (de) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxe und Behandlung von PRDC |
EP1958644A1 (de) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Vorbeugung und Behandlung von subklinischer PCVD |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
KR101225304B1 (ko) | 2007-11-06 | 2013-01-22 | 와이어쓰 엘엘씨 | 마이코플라스마 하이오뉴모니아에 비독성 항원보강된 살아있는 백신 |
MX2010007815A (es) | 2008-01-23 | 2010-08-10 | Boehringer Ingelheim Vetmed | Composiciones inmunogenicas de mycoplasma hyopneumoniae contra pcv2 y metodos para producir composiciones de este tipo. |
US8444989B1 (en) | 2008-04-18 | 2013-05-21 | Boehringer Ingelheim Vetmedica Gmbh | One dose vaccination against mycoplasma infections of pigs |
WO2009158395A1 (en) * | 2008-06-25 | 2009-12-30 | Braasch Biotech Llc | Compositions and methods for enhanced somatostatin immunogenicity |
NZ596722A (en) * | 2009-05-19 | 2013-08-30 | Univ Melbourne | A temperature sensitive vaccine strain of mycoplasma hyopneumoniae and uses thereof |
JP5968622B2 (ja) | 2009-06-04 | 2016-08-10 | 国立感染症研究所長 | マイコプラズマ感染症用ワクチン |
TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物 |
KR101746880B1 (ko) * | 2009-09-10 | 2017-06-14 | 메리얼 인코포레이티드 | 사포닌-함유 면역보강제를 포함하는 신규 백신 제형 |
JP5815676B2 (ja) | 2010-04-30 | 2015-11-17 | テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド | H5n1系列に対する汎用ワクチン |
US20150086587A1 (en) * | 2012-03-28 | 2015-03-26 | Kansas State University Research Foundation | Vaccine adjuvant |
UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
UA114503C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
CN103623400B (zh) * | 2012-08-24 | 2016-08-17 | 普莱柯生物工程股份有限公司 | 抗猪支原体肺炎、传染性胸膜肺炎疫苗组合物及制备方法 |
JP6122146B2 (ja) | 2012-12-28 | 2017-04-26 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーBoehringer Ingelheim Vetmedica GmbH | マイコプラズマワクチン作製方法 |
ES2808673T3 (es) * | 2012-12-28 | 2021-03-01 | Boehringer Ingelheim Vetmedica Gmbh | Composición inmunogénica que comprende antígenos de micoplasma |
CN104338128B (zh) * | 2013-07-31 | 2017-09-05 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
DK3052516T3 (da) | 2013-10-02 | 2020-03-23 | Boehringer Ingelheim Animal Health Usa Inc | PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf |
US11883476B2 (en) * | 2017-12-04 | 2024-01-30 | Intervet Inc. | Canine lyme disease vaccine |
CN108324941A (zh) * | 2018-04-03 | 2018-07-27 | 林淑卿 | 猪疾病疫苗用佐剂及其制备方法 |
CN117100851A (zh) * | 2023-10-23 | 2023-11-24 | 成都依思康生物科技有限公司 | 一种佐剂、疫苗组合物及其制备方法和应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) * | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US3790665A (en) * | 1968-02-23 | 1974-02-05 | Haver Lockhart Labor Inc | Injectable adjuvant,method of preparing same and compositions including such adjuvant |
US4606918A (en) * | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
CA1267087A (en) * | 1985-02-14 | 1990-03-27 | Nicolaas Visser | Synthetic immunogen |
EP0283085B1 (de) | 1987-03-17 | 1992-11-11 | Akzo N.V. | Adjuvanzienmischung |
DE3855807T2 (de) * | 1987-11-03 | 1997-06-12 | Syntex (U.S.A.) Inc., Palo Alto, Calif. | Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans |
US5240706A (en) * | 1989-04-07 | 1993-08-31 | Ml Technology Ventures, L.P. | Intranasal administration of Mycoplasma hyopneumoniae antigen |
US6113916A (en) * | 1990-05-29 | 2000-09-05 | American Cyanamid Company | Method of enhancing cell mediated immune responses |
DE69128361T3 (de) | 1990-05-29 | 2006-04-13 | Wyeth Holdings Corp. | Impfstoff gegen die pneumonie bei schweinen und verfahren zu seiner herstellung |
US5695769A (en) * | 1990-06-13 | 1997-12-09 | Pfizer Inc. | Pasteurella multocida toxoid vaccines |
US5565205A (en) | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
DE69232969T2 (de) | 1991-11-15 | 2004-08-05 | Pfizer Inc. | Methode zur herstellung von gram-negativen bakteriellen vakzinen |
US5338543A (en) * | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
US5534256A (en) * | 1992-07-02 | 1996-07-09 | University Of Saskatchewan | Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins |
JP3265095B2 (ja) * | 1993-11-19 | 2002-03-11 | 本田技研工業株式会社 | キャニスタ |
ATE365049T1 (de) * | 1994-05-10 | 2007-07-15 | Wyeth Corp | Abgeänderter, verbesserter brsv lebend- impfstoff |
US5820869A (en) * | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
DE19601754A1 (de) * | 1996-01-19 | 1997-07-24 | Hoechst Ag | Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung |
US5846735A (en) * | 1996-04-18 | 1998-12-08 | University Of Iowa Research Foundation | Hepatitis C virus Fc-binding function |
EP0948625B1 (de) * | 1996-12-20 | 2011-01-26 | The Board Of Regents, The University Of Texas System | Moraxella catarrhalis antigene uspa1 und uspa2 |
FR2775601B1 (fr) * | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
US6342231B1 (en) * | 1998-07-01 | 2002-01-29 | Akzo Nobel N.V. | Haemophilus parasuis vaccine and diagnostic |
US6632439B2 (en) * | 1999-09-29 | 2003-10-14 | Novartis Animal Health, Inc. | Fusobacterium necrophorum vaccine and method for making such vaccine |
US6585981B1 (en) * | 2000-07-27 | 2003-07-01 | Regents Of The University Of Minnesota | Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae |
MY129765A (en) * | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
US7018638B2 (en) * | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
DK2842569T3 (da) * | 2001-07-02 | 2019-05-20 | Zoetis Services Llc | Vaccination i en dosis med Mycoplasma hyopneumoniae |
WO2003074026A1 (en) * | 2002-03-07 | 2003-09-12 | Biocompatibles Uk Limited | Drug carriers comprising amphiphilic block copolymers |
ITMI20030269A1 (it) * | 2003-02-14 | 2004-08-15 | Advance Holdings Ltd | Sale di cetilpiridino di un agente antiinfiammatorio |
US8052762B1 (en) * | 2010-09-02 | 2011-11-08 | Kelly Van Gogh, LLC | Compositions for dyeing keratin-containing fibers |
-
2001
- 2001-11-27 MY MYPI20015418A patent/MY129765A/en unknown
- 2001-12-11 DE DE60127994T patent/DE60127994T2/de not_active Expired - Lifetime
- 2001-12-11 PT PT01990123T patent/PT1343525E/pt unknown
- 2001-12-11 AT AT01990123T patent/ATE359813T1/de active
- 2001-12-11 WO PCT/US2001/047865 patent/WO2002049666A2/en active IP Right Grant
- 2001-12-11 ME MEP-2008-859A patent/ME00570B/me unknown
- 2001-12-11 NZ NZ526904A patent/NZ526904A/en not_active IP Right Cessation
- 2001-12-11 MX MXPA03005357A patent/MXPA03005357A/es active IP Right Grant
- 2001-12-11 JP JP2002551004A patent/JP5074656B2/ja not_active Expired - Lifetime
- 2001-12-11 AU AU2002228993A patent/AU2002228993B2/en not_active Expired
- 2001-12-11 EP EP01990123A patent/EP1343525B1/de not_active Expired - Lifetime
- 2001-12-11 AU AU2899302A patent/AU2899302A/xx active Pending
- 2001-12-11 KR KR1020037008293A patent/KR100874119B1/ko active IP Right Grant
- 2001-12-11 ES ES01990123T patent/ES2283452T3/es not_active Expired - Lifetime
- 2001-12-11 HU HU0400687A patent/HU227431B1/hu unknown
- 2001-12-11 PL PL363220A patent/PL211174B1/pl unknown
- 2001-12-11 DK DK01990123T patent/DK1343525T3/da active
- 2001-12-11 CZ CZ2003-1721A patent/CZ307075B6/cs not_active IP Right Cessation
- 2001-12-11 CN CNB018226345A patent/CN1296095C/zh not_active Expired - Lifetime
- 2001-12-11 BR BRPI0116249A patent/BRPI0116249B1/pt active IP Right Grant
- 2001-12-11 RS YUP-493/03A patent/RS51536B/sr unknown
- 2001-12-14 TW TW090131039A patent/TWI308872B/zh not_active IP Right Cessation
- 2001-12-18 AR ARP010105861A patent/AR033410A1/es not_active Application Discontinuation
-
2002
- 2002-01-08 US US10/039,383 patent/US20020131980A1/en not_active Abandoned
-
2003
- 2003-06-11 BG BG107898A patent/BG66213B1/bg unknown
- 2003-07-17 ZA ZA200305545A patent/ZA200305545B/en unknown
- 2003-07-18 HR HR20030585A patent/HRP20030585B1/xx not_active IP Right Cessation
- 2003-12-09 HK HK03108934A patent/HK1056513A1/xx not_active IP Right Cessation
-
2006
- 2006-08-21 US US11/507,231 patent/US7666439B2/en not_active Expired - Lifetime
-
2007
- 2007-06-21 CY CY20071100827T patent/CY1106669T1/el unknown
-
2008
- 2008-11-13 JP JP2008291001A patent/JP2009073855A/ja active Pending
-
2010
- 2010-01-22 US US12/692,275 patent/US8187588B2/en not_active Expired - Fee Related
-
2012
- 2012-04-27 US US13/458,541 patent/US9238065B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002228993B2 (en) | Mycoplasma hyopneumoniae bacterin vaccine | |
EP1870109B1 (de) | Kombinationsimpfstoff gegen mycoplasma hyopneumoniae und porzine circovirus |